# Insulin-Resistance Research: 5-Amino-1MQ, MOTS-c & NAD+

**Quick answer:** 5-Amino-1MQ, [MOTS-c](https://portaltowellness.net/research/mitochondrial-peptide-comparison-ss31-mots-c-nad/) , and [NAD+](https://portaltowellness.net/research/what-is-nad-plus/) are studied in metabolic and insulin-signaling research through different pathways. 5-Amino-1MQ is researched as an NNMT inhibitor linked to GLUT4 glucose-transport and NAD+ levels; MOTS-c as an AMPK activator regulating fat oxidation and insulin sensitivity; and NAD+ as the coenzyme supporting insulin-signaling metabolism. *Sold for research use only.*

## What each is studied for

**5-Amino-1MQ** is a small-molecule inhibitor of NNMT (nicotinamide N-methyltransferase), an enzyme associated with fat storage and metabolic rate in research. The insulin-signaling research angle involves increased GLUT4 transporter expression (studied for moving more glucose into muscle cells) and preserved NAD+ levels (studied for supporting insulin responsiveness). A widely cited UT Southwestern study reported that NNMT inhibition reduced fat mass by ~30% in diet-induced obese mice *without altering food intake* — an animal research finding, not a human outcome.

**MOTS-c** is a mitochondrial-derived peptide studied as an activator of AMPK (AMP-activated protein kinase), the metabolic “master switch” that shifts cells toward fat oxidation. MOTS-c research examines metabolic homeostasis, insulin sensitivity, and exercise capacity.

**NAD+** is the coenzyme that powers mitochondrial energy production and sirtuin/DNA-repair pathways. In metabolic research, adequate NAD+ is studied for supporting healthy insulin signaling and glucose uptake. (NAD+ also appears in our Longevity pillar — it spans both research areas.)

## How the pathways differ

| Compound | Primary studied target | Research angle |
| --- | --- | --- |
| **5-Amino-1MQ** | NNMT inhibition | GLUT4 glucose transport; NAD+ preservation; fat-storage research |
| **MOTS-c** | AMPK activation | Fat oxidation, insulin sensitivity, metabolic homeostasis |
| **NAD+** | Coenzyme / sirtuin pathways | Mitochondrial energy and insulin-signaling support |

## Why they’re studied together

The most-investigated combination pairs **5-Amino-1MQ (NNMT inhibition)** with **MOTS-c (AMPK activation)** to target fat oxidation and glucose handling through two complementary pathways, often alongside **NAD+** to support the underlying coenzyme pool. For incretin-pathway metabolic research (semaglutide, tirzepatide, retatrutide), see our [GLP-1 pillar](https://portaltowellness.net/research/glp1-adjunct-peptide-research-guide/) .

## Frequently asked questions

**What peptides are studied for insulin resistance?**
In metabolic research, 5-Amino-1MQ (NNMT inhibitor), MOTS-c (AMPK activator), and NAD+ (coenzyme) are commonly studied for insulin-signaling pathways, alongside the GLP-1 class.

**What is the difference between 5-Amino-1MQ and MOTS-c?**
5-Amino-1MQ inhibits the NNMT enzyme and is studied for GLUT4 and NAD+ pathways; MOTS-c activates AMPK and is studied for fat oxidation and mitochondrial metabolism. They’re researched as complementary.

**What does NNMT inhibition do in research?**
Animal studies associate NNMT inhibition with reduced fat mass and preserved NAD+ levels; 5-Amino-1MQ is the most-studied NNMT inhibitor in this space.

**Is NAD+ related to insulin sensitivity?**
Research suggests adequate NAD+ supports insulin signaling and glucose uptake, which is why it appears in both metabolic and longevity research.

**Are these for human use?**
No. Portal to Wellness sells these strictly for laboratory and research use only. Nothing here is medical advice.

## Primary-literature anchors

Cite primary sources: Kraus et al. / UT Southwestern NNMT-inhibition obesity research; Lee et al., MOTS-c and AMPK ( *Cell Metabolism* , 2015); NAD+ metabolism and insulin-signaling reviews. Link via PubMed.

---

*For research use only. Not for human or veterinary use, diagnosis, treatment, or prevention of any condition. Not evaluated by the FDA. Author: Charles Fowler. Last updated: May 2026.*

---

Source: https://portaltowellness.net/insulin-resistance-research-peptides/
Research use only. Terms: https://portaltowellness.net/research-use-only/